Mark Cuban Low Cost Drug Company
The Mark Cuban Cost Plus Drugs Company and EmsanaRx, PBC, a pharmacy benefit manager (PBM) built by employers, for employers, entered into a partnership with the launch of a collaboration with the launch of EmsanaRx Plus. The two companies describe EmsanaRx Plus as a “first-of-its-kind” supplemental drug discount product designed specifically for employers as a standalone pipeline for lower-cost medicines that have been contracted directly with drug manufacturers by Cost Plus Drugs.
“Like Cost Plus Drugs, EmsanaRx is working to disrupt the current pharmacy supply chain to eliminate the unnecessary markup and profiteering that is burdening businesses and consumers with high drug costs,” said Mark Cuban in a statement. “By partnering with a company as committed to transparency as Cost Plus Drugs, and with the technological capabilities to customize to the needs of self-funded employers, we are able to bring lower-cost medicines to a wider swath of the American public.”
Founded in 2016 and based in Dallas, The Mark Cuban Cost Plus Drug Company declares that it is dedicated to producing low-cost versions of high-cost generic drugs. It pledges to provide radical transparency in how the company prices its drugs and that it will let everyone know what it costs to manufacture, distribute, and market their drugs to pharmacies.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
The company promises, “no hidden costs, no middlemen, no rebates only available to insurance companies. Everybody gets the same low price for every drug we make.”
Mark Cuban Cost Plus Drugs said that the relationship with EmsanaRx enables the company to offer its low-cost medications to employers due to EmsanaRx’s ability to integrate with employer-sponsored drug benefits. “This relationship offers added value to existing employer-based prescription benefit coverage,” said the company.
Currently, when employee members use prescription drug discount card options, employers lose access to critical information and employees spend money on medications that doesn’t apply to their health plan deductible or maximum out-of-pocket costs. EmsanaRx Plus will provide deep discounts on medications without employees having to go outside of their health plan benefits to realize those savings, ensuring greater continuity of care. EmsanaRx Plus advocates will assist both employers and employees interested in transferring their medications to a lower-cost option, and coordinate with providers on behalf of patients.
“Employers are increasingly recognizing that they’re being held hostage by a consolidated industry playing games that cost them more every year without adding value,” said Greg Baker, CEO of EmsanaRx. “In partnering with Cost Plus Drugs, we will help employers understand where high-cost drugs are a problem in their current benefit design and give them and their employees access to lower-cost alternatives.”
